强生收购要约报告后Nanobiotix上涨

2026-03-25 19:03

Nanobiotix (NBTX) shares rose ~7% in Paris on Wednesday after the French publication La Lettre reported that U.S. pharma giant Johnson & Johnson (JNJ) is eyeing a buyout deal to acquire the cancer drug developer.
Paris-based Nanobiotix (NBTX) has an ongoing partnership with J&J (JNJ) to jointly develop and commercialize its lead asset, JNJ-1900 (NBTXR3), under a license agreement signed with the New Jersey-based drugmaker in 2023.
Its shares climbed in October in reaction to initial results from a Phase 1 trial designed to evaluate the intratumoral injection as part of a combination regimen for a type of esophageal cancer called locally advanced adenocarcinoma of the esophagus.
Nanobiotix (NBTX) has surged more than 700% in value over the past 12 months, giving it a market capitalization of $1.5B
Johnson & Johnson (JNJ) and Nanobiotix (NBTX) were not immediately available for requests for comments.

More on Nanobiotix, Johnson & Johnson